시장보고서
상품코드
1823785

저분자 CMO/CDMO 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Small Molecule CMO/CDMO Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

발행일: | 리서치사: Persistence Market Research | 페이지 정보: 영문 184 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Persistence Market Research는 이번에 세계의 저분자 CMO/CDMO 시장에 관한 광범위한 리포트를 발행했습니다. 시장 성장 촉진요인·동향·기회·과제 등의 주요 시장 역학을 종합적으로 분석하고, 시장 구조에 관한 심층 인사이트를 제공하고 있습니다.

주요 인사이트

  • 저분자 CMO/CDMO 시장 규모(2025 E) : 792억 8,000만 달러
  • 예측 시장 규모(2032년) : 1,141억 7,000만 달러
  • 세계 시장 성장률(CAGR 2025 to 2032) : 5.3%

저분자 CMO/CDMO 시장 - 리포트 범위 :

저분자 CMO/CDMO 시장에는 저분자 의약품 제조 위탁 및 시장 개발 위탁 서비스가 광범위하게 포함됩니다. 이러한 서비스는 제약 및 생명공학 기업을 위해 설계되었으며, 의약품 개발, 제형화, 제조, 포장에 대한 엔드 투 엔드 솔루션을 제공합니다. 이 시장은 대형 제약사, 신생 바이오테크놀러지 기업, 제네릭 제약사 등 다양한 부문에 서비스를 제공합니다. 성장의 원동력은 아웃소싱 동향, 비용 효율성 향상, 의약품 제형 및 제조 전문 지식에 대한 수요 증가입니다.

시장 성장 촉진요인:

세계 저분자 CMO/CDMO 시장을 주도하는 몇 가지 주요 요인이 있습니다. 비용적 장점과 높은 업무 효율성으로 인해 의약품 제조 공정의 아웃소싱에 대한 수요가 증가하고 있는 것이 시장 성장의 원동력이 되고 있습니다. 또한 의약품 승인 건수 증가와 저분자 의약품의 복잡성으로 인해 제약기업은 전문 제조 파트너를 찾게 되었습니다. 연속 생산 및 고역가 원료의약품(HPAPI) 제조와 같은 첨단 제조기술의 통합은 시장 확대를 더욱 촉진하고 있습니다. 또한 규제 대응 및 GMP(Good Manufacturing Practice) 전문 지식의 필요성이 전문 CMO/CDMO와의 제휴를 촉진하고 있습니다.

시장 성장 억제요인:

유망 성장 전망에도 불구하고 저분자 CMO/CDMO 시장은 엄격한 규제 요건과 지적재산권 관련 과제에 직면해 있습니다. 미국 FDA, 유럽의약품청(EMA), 기타 규제 당국에 대한 대응 등 수탁제조업체에 대한 복잡한 승인 프로세스는 제조 일정을 지연시킬 수 있습니다. 또한 제약회사는 제 3자에게 위탁할 때 자체 제제나 기술의 안전성에 대한 우려에 직면하는 경우가 많습니다. 또한 수탁제조 시설의 생산능력 제약과 첨단 기술력에 따른 높은 비용도 시장 성장의 걸림돌로 작용할 수 있습니다.

시장 기회:

암 및 중추신경계(CNS) 질환과 같은 고부가가치 및 틈새 치료 분야에 대한 수요 증가로 인해 시장은 큰 비즈니스 기회를 창출하고 있습니다. 고활성 의약품 성분(HPAPI)과 나노 분쇄 및 분무 건조와 같은 특수 제제 기술 분야의 역량 확대는 유리한 성장 가능성을 가져다 줄 것입니다. 신흥 시장, 특히 아시아태평양은 낮은 운영 비용과 양호한 규제 환경으로 인해 CMO/CDMO에게 큰 비즈니스 기회가 되고 있습니다. 또한 수탁제조 공정의 디지털 혁신과 자동화의 발전은 효율성과 확장성을 향상시켜 시장 성장을 더욱 촉진하고 있습니다.

이 보고서에서 다룬 주요 질문

  • 저분자 CMO/CDMO 시장의 세계 성장을 가속하는 주요 요인은?
  • 제약회사에서 수요가 많은 수탁제조 및 개발 서비스는 무엇인가?
  • 기술 발전은 저분자 CMO/CDMO 시장의 경쟁 환경에 어떤 영향을 미치고 있는가?
  • 저분자 CMO/CDMO 시장의 주요 기업은 어디이며, 경쟁력을 유지하기 위해 어떤 전략을 취하고 있는가?
  • 세계 저분자 CMO/CDMO 시장의 새로운 동향과 전망은?

목차

제1장 개요

제2장 시장 개요

  • 시장의 범위와 정의
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
    • 주요 동향
  • 거시경제 요인
    • 세계의 부문별 전망
    • 세계 GDP 성장 전망
  • COVID-19의 영향 분석
  • 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

  • 규제 상황
  • 제품 채택 분석
  • 밸류체인 분석
  • 주요 거래와 합병
  • PESTLE 분석
  • Porter's Five Forces 분석

제4장 세계의 저분자 CMO/CDMO 시장 전망 :

  • 주요 하이라이트
    • 시장 규모와 전년대비 성장률
    • 절대적 매출 기회
  • 시장 규모 분석과 예측
    • 과거 시장 규모 분석, 2019-2024년
    • 현재 시장 규모 분석과 예측, 2025-2032년
  • 세계의 저분자 CMO/CDMO 시장 전망 : 제품
    • 서론/주요 조사 결과
    • 과거 시장 규모 분석, 제품별, 2019-2024년
    • 현재 시장 규모 분석과 예측, 제품별, 2025-2032년
      • 표준 API
      • HP API
    • 시장의 매력 분석 : 제품
  • 세계의 저분자 CMO/CDMO 시장 전망 : 서비스
    • 서론/주요 조사 결과
    • 과거 시장 규모 분석, 서비스별, 2019-2024년
    • 현재 시장 규모 분석과 예측, 서비스별, 2025-2032년
      • 프로세스 개발
      • 분석법 개발
      • GMP 제조 서비스
      • 스케일업과 기술 이전
      • 규제 지원
      • Fill-Finish 서비스
    • 시장의 매력 분석 : 서비스
  • 세계의 저분자 CMO/CDMO 시장 전망 : 기업 규모
    • 서론/주요 조사 결과
    • 과거 시장 규모 분석, 기업 규모별, 2019-2024년
    • 현재 시장 규모 분석과 예측, 기업 규모별, 2025-2032년
      • 소규모
      • 중규모
      • 대규모
    • 시장의 매력 분석 : 기업 규모
  • 세계의 저분자 CMO/CDMO 시장 전망 : 사업 규모
    • 서론/주요 조사 결과
    • 과거 시장 규모 분석, 사업 규모별, 2019-2024년
    • 현재 시장 규모 분석과 예측, 사업 규모별, 2025-2032년
      • 임상
      • 상용
    • 시장의 매력 분석 : 사업 규모

제5장 세계의 저분자 CMO/CDMO 시장 전망 : 지역

  • 주요 하이라이트
  • 과거 시장 규모 분석, 지역별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 지역별, 2025-2032년
    • 북미
    • 유럽
    • 동아시아
    • 남아시아와 오세아니아
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 분석 : 지역

제6장 북미의 저분자 CMO/CDMO 시장 전망 :

제7장 유럽의 저분자 CMO/CDMO 시장 전망 :

제8장 동아시아의 저분자 CMO/CDMO 시장 전망

제9장 남아시아 및 오세아니아의 저분자 CMO/CDMO 시장 전망 :

제10장 라틴아메리카의 저분자 CMO/CDMO 시장 전망 :

제11장 중동 및 아프리카의 저분자 CMO/CDMO 시장 전망 :

제12장 경쟁 구도

  • 시장 점유율 분석, 2024년
  • 시장 구조
    • 시장별 경쟁 격화 맵
    • 경쟁 대시보드
  • 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
    • Lonza
    • Pfizer CentreOne(Pfizer Inc.)
    • Piramal Pharma Solutions
    • Wuxi App Tec
    • Patheon(Thermo Fisher Scientific Inc.)
    • Ajinomoto Bio-Pharma Solutions
    • Siegfried Holding AG
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd.
    • Asymchema
    • PCI Pharma Services
    • Almac Group
    • Labcorp Drug Development
    • Sumitomo Chemical Co., Ltd.
    • ICROM
    • AGC Inc.
    • FUJIFILM Corporation
    • CMIC HOLDINGS Co., LTD.
    • Evonik
    • Terumo Pharmaceutical Solutions(TPS)

제13장 부록

  • 조사 방법
  • 조사의 전제
  • 두자어와 약어
KSA 25.10.10

Persistence Market Research has recently published an extensive report on the global Small Molecule CMO/CDMO Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Small Molecule CMO/CDMO Market Size (2025E): USD 79.28 Bn
  • Projected Market Value (2032F): USD 114.17 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Small Molecule CMO/CDMO Market - Report Scope:

The Small Molecule CMO/CDMO Market encompasses a broad range of contract manufacturing and contract development services for pharmaceutical small molecules. These services are designed to cater to pharmaceutical and biotechnology companies, providing end-to-end solutions for drug development, formulation, production, and packaging. The market serves various segments, including large pharmaceutical firms, emerging biotech companies, and generic drug manufacturers. Growth is driven by increasing outsourcing trends, cost-efficiency, and the rising demand for specialized expertise in drug formulation and production.

Market Growth Drivers:

Several key factors are driving the global Small Molecule CMO/CDMO Market. The rising demand for outsourcing pharmaceutical manufacturing processes due to cost advantages and operational efficiencies is fueling market growth. Additionally, the increasing number of drug approvals and the growing complexity of small molecule drugs have led pharmaceutical companies to seek specialized manufacturing partners. The integration of advanced manufacturing technologies such as continuous manufacturing and high-potency API (HPAPI) production is further supporting market expansion. Furthermore, regulatory compliance and the need for expertise in Good Manufacturing Practices (GMP) are encouraging companies to collaborate with specialized CMO/CDMOs.

Market Restraints:

Despite promising growth prospects, the Small Molecule CMO/CDMO Market faces challenges related to stringent regulatory requirements and intellectual property concerns. The complex approval processes for contract manufacturers, including compliance with the U.S. FDA, EMA, and other regulatory agencies, can delay production timelines. Additionally, pharmaceutical companies often face concerns about the security of proprietary formulations and technologies when outsourcing to third parties. Market growth can also be hindered by capacity constraints at contract manufacturing facilities and the high costs associated with advanced technological capabilities.

Market Opportunities:

The market presents significant opportunities driven by the increasing demand for high-value and niche therapeutic applications, including oncology and central nervous system (CNS) disorders. The expansion of capabilities in high-potency active pharmaceutical ingredients (HPAPIs) and specialized formulation techniques, such as nano-milling and spray drying, provides lucrative growth potential. Emerging markets, particularly in Asia-Pacific, present significant opportunities for CMO/CDMOs due to lower operational costs and favorable regulatory environments. Additionally, advancements in digital transformation and automation in contract manufacturing processes are improving efficiency and scalability, further driving market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
  • Which contract manufacturing and development services are in high demand across pharmaceutical companies?
  • How are technological advancements influencing the competitive landscape of the Small Molecule CMO/CDMO Market?
  • Who are the key players in the Small Molecule CMO/CDMO Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Small Molecule CMO/CDMO Market, including Lonza Group, Catalent Inc., and WuXi AppTec, focus on innovation, capacity expansion, and strategic collaborations to gain a competitive edge. These companies invest in R&D to enhance contract development and manufacturing capabilities while expanding their service portfolios. Collaborations with pharmaceutical firms, biotech startups, and government agencies facilitate market access and support long-term growth. Emphasis on regulatory compliance, high-quality manufacturing standards, and robust marketing strategies fosters market expansion and strengthens brand reputation in the evolving Small Molecule CMO/CDMO Market landscape.

Key Companies Profiled:

  • Lonza
  • Pfizer CentreOne (Pfizer Inc.)
  • Piramal Pharma Solutions
  • Wuxi App Tec
  • Patheon (Thermo Fisher Scientific Inc.)
  • Ajinomoto Bio-Pharma Solutions
  • Siegfried Holding AG
  • Eurofins Scientific
  • Aurigene Pharmaceutical Services Ltd.
  • Asymchema
  • PCI Pharma Services
  • Almac Group
  • Labcorp Drug Development
  • Sumitomo Chemical Co., Ltd.
  • ICROM
  • AGC Inc.
  • FUJIFILM Corporation
  • CMIC HOLDINGS Co., LTD.
  • Evonik
  • Terumo Pharmaceutical Solutions (TPS)

Small Molecule CMO/CDMO Market Segmentation

By Product

  • Standard API
  • HP API

By Service

  • Process Development
  • Analytical Method Development
  • GMP Manufacturing Service
  • Scale-up and Tech Transfer
  • Regulatory Assistance
  • Fill-finish Services

By Company Size

  • Small
  • Mid-sized
  • Large

By Scale of Operation

  • Clinical
  • Commercial

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Small Molecule CMO/CDMO Market Outlook
  • 1.2. Global Small Molecule CMO/CDMO Market Outlook: Services
  • 1.3. Introduction/Key Findings
  • 1.4. Historical Market Size (US$ Bn ) and Analysis, By Services, 2019-2024
  • 1.5. Current Market Size (US$ Bn ) and Analysis and Forecast, By Services, 2025-2032
  • 1.6. Key Market Trends
  • 1.7. Future Market Projections
  • 1.8. Premium Market Insights
  • 1.9. Industry Developments and Key Market Events
  • 1.10. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Small Molecule CMO/CDMO Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn ) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn ) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn ) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn ) Analysis and Forecast, 2025-2032
  • 4.3. Global Small Molecule CMO/CDMO Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn ) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Standard API
      • 4.3.3.2. HP API
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Small Molecule CMO/CDMO Market Outlook: Service
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn ) Analysis, By Service, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
      • 4.4.3.1. Process Development
      • 4.4.3.2. Analytical Method Development
      • 4.4.3.3. GMP Manufacturing Service
      • 4.4.3.4. Scale-up and Tech Transfer
      • 4.4.3.5. Regulatory Assistance
      • 4.4.3.6. Fill-Finish Services
    • 4.4.4. Market Attractiveness Analysis: Service
  • 4.5. Global Small Molecule CMO/CDMO Market Outlook: Company Size
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn ) Analysis, By Company Size, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
      • 4.5.3.1. Small
      • 4.5.3.2. Mid-sized
      • 4.5.3.3. Large
    • 4.5.4. Market Attractiveness Analysis: Company Size
  • 4.6. Global Small Molecule CMO/CDMO Market Outlook: Scale of Operation
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn ) Analysis, By Scale of Operation, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
      • 4.6.3.1. Clinical
      • 4.6.3.2. Commercial
    • 4.6.4. Market Attractiveness Analysis: Scale of Operation

5. Global Small Molecule CMO/CDMO Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn ) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Small Molecule CMO/CDMO Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Service
    • 6.2.4. By Company Size
    • 6.2.5. By Scale of Operation
  • 6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Standard API
    • 6.4.2. HP API
  • 6.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 6.5.1. Process Development
    • 6.5.2. Analytical Method Development
    • 6.5.3. GMP Manufacturing Service
    • 6.5.4. Scale-up and Tech Transfer
    • 6.5.5. Regulatory Assistance
    • 6.5.6. Fill-Finish Services
  • 6.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 6.6.1. Small
    • 6.6.2. Mid-sized
    • 6.6.3. Large
  • 6.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 6.7.1. Clinical
    • 6.7.2. Commercial
  • 6.8. Market Attractiveness Analysis

7. Europe Small Molecule CMO/CDMO Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Service
    • 7.2.4. By Company Size
    • 7.2.5. By Scale of Operation
  • 7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Standard API
    • 7.4.2. HP API
  • 7.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 7.5.1. Process Development
    • 7.5.2. Analytical Method Development
    • 7.5.3. GMP Manufacturing Service
    • 7.5.4. Scale-up and Tech Transfer
    • 7.5.5. Regulatory Assistance
    • 7.5.6. Fill-Finish Services
  • 7.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 7.6.1. Small
    • 7.6.2. Mid-sized
    • 7.6.3. Large
  • 7.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 7.7.1. Clinical
    • 7.7.2. Commercial
  • 7.8. Market Attractiveness Analysis

8. East Asia Small Molecule CMO/CDMO Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Service
    • 8.2.4. By Company Size
    • 8.2.5. By Scale of Operation
  • 8.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Standard API
    • 8.4.2. HP API
  • 8.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 8.5.1. Process Development
    • 8.5.2. Analytical Method Development
    • 8.5.3. GMP Manufacturing Service
    • 8.5.4. Scale-up and Tech Transfer
    • 8.5.5. Regulatory Assistance
    • 8.5.6. Fill-Finish Services
  • 8.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 8.6.1. Small
    • 8.6.2. Mid-sized
    • 8.6.3. Large
  • 8.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 8.7.1. Clinical
    • 8.7.2. Commercial
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Small Molecule CMO/CDMO Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Service
    • 9.2.4. By Company Size
    • 9.2.5. By Scale of Operation
  • 9.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Standard API
    • 9.4.2. HP API
  • 9.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 9.5.1. Process Development
    • 9.5.2. Analytical Method Development
    • 9.5.3. GMP Manufacturing Service
    • 9.5.4. Scale-up and Tech Transfer
    • 9.5.5. Regulatory Assistance
    • 9.5.6. Fill-Finish Services
  • 9.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 9.6.1. Small
    • 9.6.2. Mid-sized
    • 9.6.3. Large
  • 9.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 9.7.1. Clinical
    • 9.7.2. Commercial
  • 9.8. Market Attractiveness Analysis

10. Latin America Small Molecule CMO/CDMO Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Service
    • 10.2.4. By Company Size
    • 10.2.5. By Scale of Operation
  • 10.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Standard API
    • 10.4.2. HP API
  • 10.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 10.5.1. Process Development
    • 10.5.2. Analytical Method Development
    • 10.5.3. GMP Manufacturing Service
    • 10.5.4. Scale-up and Tech Transfer
    • 10.5.5. Regulatory Assistance
    • 10.5.6. Fill-Finish Services
  • 10.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 10.6.1. Small
    • 10.6.2. Mid-sized
    • 10.6.3. Large
  • 10.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 10.7.1. Clinical
    • 10.7.2. Commercial
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Small Molecule CMO/CDMO Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Service
    • 11.2.4. By Company Size
    • 11.2.5. By Scale of Operation
  • 11.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Standard API
    • 11.4.2. HP API
  • 11.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Service, 2025-2032
    • 11.5.1. Process Development
    • 11.5.2. Analytical Method Development
    • 11.5.3. GMP Manufacturing Service
    • 11.5.4. Scale-up and Tech Transfer
    • 11.5.5. Regulatory Assistance
    • 11.5.6. Fill-Finish Services
  • 11.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Company Size, 2025-2032
    • 11.6.1. Small
    • 11.6.2. Mid-sized
    • 11.6.3. Large
  • 11.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 11.7.1. Clinical
    • 11.7.2. Commercial
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Lonza
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Pfizer CentreOne (Pfizer Inc.)
    • 12.3.3. Piramal Pharma Solutions
    • 12.3.4. Wuxi App Tec
    • 12.3.5. Patheon (Thermo Fisher Scientific Inc.)
    • 12.3.6. Ajinomoto Bio-Pharma Solutions
    • 12.3.7. Siegfried Holding AG
    • 12.3.8. Eurofins Scientific
    • 12.3.9. Aurigene Pharmaceutical Services Ltd.
    • 12.3.10. Asymchema
    • 12.3.11. PCI Pharma Services
    • 12.3.12. Almac Group
    • 12.3.13. Labcorp Drug Development
    • 12.3.14. Sumitomo Chemical Co., Ltd.
    • 12.3.15. ICROM
    • 12.3.16. AGC Inc.
    • 12.3.17. FUJIFILM Corporation
    • 12.3.18. CMIC HOLDINGS Co., LTD.
    • 12.3.19.Evonik
    • 12.3.20. Terumo Pharmaceutical Solutions (TPS)

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제